The incidence and relative risk of PD-1/PD-L1 inhibitors-related colitis in non-small cell lung cancer: A meta-analysis of randomized controlled trials.
CONCLUSION: Our meta-analysis indicates when compared with control group, the PD-1/PD-L1 inhibitors may lead to a higher risk of all grade and high grade immune-mediated colitis, but may result in a reduction in all grade diarrhea. PD-1 inhibitors in NSCLC patients, but not PD-L1 inhibitors, increase the risk of all- and high grade colitis. These results suggest that clinicians shall pay more attention to this rare but life-threatening toxic effect.
PMID: 31704288 [PubMed - as supplied by publisher]
Source: International Immunopharmacology - Category: Allergy & Immunology Authors: Lin LL, Lin GF, Luo Q, Chen XQ Tags: Int Immunopharmacol Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Databases & Libraries | Lung Cancer | Non-Small Cell Lung Cancer | Science | Statistics | Toxicology